Number of the records: 1
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
- 1.
SYSNO ASEP 0542897 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients Author(s) Raková, J. (CZ)
Truxová, I. (CZ)
Holicek, P. (CZ)
Šálek, C. (CZ)
Hensler, M. (CZ)
Kašíková, L. (CZ)
Pasulka, J. (CZ)
Holubová, M. (CZ)
Kovář, Marek (MBU-M) RID, ORCID
Lysák, D. (CZ)
Kline, J. P. (US)
Ráčil, Z. (CZ)
Galluzzi, L. (US)
Spíšek, R. (CZ)
Fučíková, J. (CZ)Article number 1889822 Source Title Oncoimmunology - ISSN 2162-402X
Roč. 10, č. 1 (2021)Number of pages 13 s. Language eng - English Country US - United States Keywords Co-inhibitory receptor ; innate lymphoid cells ; lag-3 ; tigit ; vista Subject RIV EE - Microbiology, Virology OECD category Microbiology Method of publishing Open access Institutional support MBU-M - RVO:61388971 UT WOS 000627790900001 EID SCOPUS 85102181179 DOI 10.1080/2162402X.2021.1889822 Annotation Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8(+) cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have limited clinical efficacy in patients with AML. Natural killer (NK) cells are central players in AML-targeting immune responses. However, little is known on the relationship between co-inhibitory receptors expressed by NK cells and the ability of the latter to control AML. Here, we show that hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) is highly expressed by NK cells from AML patients, correlating with improved functional licensing and superior effector functions. Altogether, our data indicate that NK cell frequency as well as TIM-3 expression levels constitute prognostically relevant biomarkers of active immunity against AML. Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2022 Electronic address https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1889822
Number of the records: 1